In the biopharmaceutical industry, cross-contamination is a significant concern, with potential impacts on product safety, efficacy, and ultimately, patient health. Cross-contamination occurs when trace amounts of one product inadvertently mix with another product, equipment, or process stream. This can lead to compromised product integrity, regulatory non-compliance, and costly recalls. From a quality assurance (QA) perspective,
Blog
What should we expect from Validation 4.0 Validation by design a.k.a Validation 4.0 is a new approach to validation in the biopharmaceutical industry that is designed to be more efficient, effective, and compliant with regulatory requirements. It is based on the principles of risk-based thinking, quality by design, and data integrity by design. Key
Computerized System Assurance (CSA) is a modern approach to validating automated systems, particularly in the life sciences industry. It emphasizes a risk-based methodology, focusing on product quality and patient safety, rather than the traditional, more burdensome Computer System Validation (CSV) approach [1], [2]. This article delves into the intricacies of CSA, highlighting the dos and
The use of artificial intelligence and machine learning in the pharmaceutical industry holds immense promise for overcoming drug shortages. By leveraging predictive analytics, real-time demand forecasting, quality control, regulatory compliance, inventory management, and early warning systems, AI and ML can help ensure that patients have reliable access to the medications they need.
N-nitrosamine impurities, a class of potentially carcinogenic substances, have become a significant concern in the pharmaceutical industry. These compounds can form during the drug manufacturing process or due to degradation.